"Novel antibacterial compounds and an urgent medical need create a win-win commercial opportunity"

Prolysis is an antibacterial drug discovery and development company with new classes of compounds in pre-clinical development. Novel antibacterial drugs are urgently needed to treat hospital-acquired and community-associated infections where existing therapies are failing due to antibiotic resistance.

Our cost-effective business model combines our internal expertise in bacterial cell biology with structural biology, cheminformatics and medicinal chemistry from our technology partners. This has enabled Prolysis to create a multi-project, pre-clinical portfolio. Prolysis will commercialise its new antibacterial drugs by out-licensing after demonstrating proof-of-concept in human studies.